Drug discovery and development – Page 32
-
Review
Introduction to biological and small molecule drug research and development
Big molecule pharma
-
News
Croatia's vaccines manufacturer left hanging as it enters administration
Lack of government investment puts national immunology institute in crisis
-
Opinion
Is there a drug for that?
Derek Lowe ponders whether anything is truly ‘undruggable’ if we look in the right places
-
Opinion
Put the chemistry back in medicinal chemistry
Pursuing skewed priorities and easy options has impoverished the pharmaceutical industry, says David Lathbury.
-
Opinion
Rolling boulders uphill
Is Derek Lowe troubled by his failure to develop a compound that has made it to the pharmacy shelf?
-
Opinion
Natural born chemists
Redesigning nature’s catalysts is tantalising but tricky, says Derek Lowe
-
Business
GSK to apply for malaria vaccine approval
Infection protection drops over time, but the firm will go ahead with regulatory submission
-
Feature
Re-arming the antibiotic arsenal
How can we make new antibiotics? Phillip Broadwith takes a look
-
Careers
Non-profit pharma
Not-for-profit drug discovery is growing into a promising niche employment opportunity within the pharmaceutical industry. James Mitchell Crow investigates
-
Business
Service with a smile
Company profile: Charnwood Molecular is more than a run-of-the-mill contract synthesis provider
-
Feature
Animal pharm
Making drugs to treat animals is potentially lucrative – but also difficult, as Clare Sansom discovers
-
News
Former student sues Harvard for $10 million
PhD chemist seeks damages in row over patent royalties
-
Opinion
Target acquired
Knowing a drug’s exact biochemistry has never been a prerequisite for approval, says Derek Lowe, and nor should it be
-
Business
Data-sharing partnership for drug discovery
Collaborative project aims to assist medicinal chemistry efforts
-
Opinion
Compulsory licences: necessity or threat?
Are compulsory licences for patent-protected drugs a necessary measure, or a threat to innovation?
-
News
Antibiotic resistance is a ‘ticking time bomb’
Efforts to tackle the threat will need new thinking, but their may be no easy solutions or short cuts to new drugs
-
Opinion
New antibiotics: what's the hold up?
It’s more a research problem, than a commercial one, says Derek Lowe